Skip to main content
IART
NASDAQ Industrial Applications And Services

Integra LifeSciences Q2: Adjusted EPS $0.56 Beats, Guidance Reaffirmed, Braintree Production Begins

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$19.82
Mkt Cap
$1.537B
52W Low
$8.7
52W High
$20.49
52W Position info
128% above low
Off High info
3.3% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IART has more than doubled off its 52-week low of $8.7.

Summary

Integra LifeSciences reported Q2 adjusted EPS of $0.56, up from $0.45 a year ago, and reaffirmed its full-year guidance. The Braintree facility began production, supporting a planned Q4 SurgiMend relaunch.


Key Events · Earnings and Guidance · IART

  • Q2 Adjusted EPS Beats

    Adjusted EPS of $0.56 vs $0.45 in Q2 2025, driven by improved gross margin (61.3% vs 60.7%) and lower operating expenses.

  • Revenue Growth Modest

    Total revenue of $418.8M, up 0.8% reported and 0.7% organic. Specialty Surgery grew 1.7%, while Tissue Reconstruction declined 1.9%.

  • Full-Year Guidance Reaffirmed

    Reaffirmed 2026 adjusted EPS of $2.40–$2.50 and organic revenue growth of 0.8%–3.3%. Reported revenue guidance trimmed to $1.654B–$1.695B on FX headwinds.

  • Braintree Production Begins

    Manufacturing initiated at the Braintree facility, keeping the Q4 2026 SurgiMend relaunch on schedule — a critical step in resolving prior supply disruptions.


Analysis · IART · Industrial Applications And Services

Integra LifeSciences delivered a solid Q2, with adjusted EPS of $0.56 beating the prior year's $0.45 and revenue edging up 0.8% to $418.8 million. The company reaffirmed its full-year adjusted EPS guidance of $2.40–$2.50 and organic growth of 0.8%–3.3%, though it trimmed reported revenue guidance slightly on a stronger dollar. The Braintree manufacturing facility is now producing, keeping the SurgiMend relaunch on track for Q4 — a key milestone in the company's recovery from prior quality issues. With net debt at $1.6 billion and leverage at 4.1x, the balance sheet remains stretched, but improving cash flow and a stable outlook provide some reassurance.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IART was trading at $19.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $8.70 to $20.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IART - Latest Insights

IART
Oct 21, 2026, 1:00 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $12.43
Real-time Price: $13.21 info
Change: +$0.780 (+6%) info
Market Cap: $1.027B info
IART
Oct 21, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.25
Real-time Price: $13.21 info
Change: -$0.040 (-0.30%) info
Market Cap: $1.027B info
IART
Oct 21, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $13.25
Real-time Price: $13.21 info
Change: -$0.040 (-0.30%) info
Market Cap: $1.027B info
IART
Oct 19, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.45
Real-time Price: $13.21 info
Change: -$0.240 (-2%) info
Market Cap: $1.027B info
IART
Oct 09, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.44
Real-time Price: $13.21 info
Change: -$0.230 (-2%) info
Market Cap: $1.027B info